Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan

Group 1 - Shares of Novo Nordisk and Eli Lilly experienced a decline on Tuesday due to a report indicating that price cuts are forthcoming for their popular weight-loss drugs [1]